Cagrilintide user experiences: what users themselves report
Users’ own accounts, not research. The accounts are self-selected and prove neither that it works nor that it is safe.
This page does not list users’ doses or sellers, and no figure on it is a recommendation. Doses used in studies, with sources: Cagrilintide dosage in studies.
In short
Of 126 people, 74 (59%) said cagrilintide brought some benefit and 78 (62%) some harm.
- An AI model read and classified 300 public Reddit posts one by one, following written instructions. Leaving out posts that looked like marketing, 142 were first-hand accounts, from 126 different people.
- Benefits mentioned most often: less appetite and food noise (51, 40%), weight loss (30, 24%) and more energy or alertness (1, 1%).
- Harms mentioned most often: fatigue (35, 28%), nausea (22, 17%) and food aversion or eating too little (15, 12%). In addition, 24 (19%) described some other, rarer harm. People tend to post when something goes wrong, so this share does not tell how common harms are.
- Cagrilintide has no marketing authorisation, so most accounts are about products whose contents are unknown. 87 of 126 people (69%) used other substances at the same time, most often a GLP-1 drug: retatrutide (37), tirzepatide (36) and semaglutide (18). So the figures mostly describe combined use.
- The accounts cannot separate the substance from placebo or other causes. What the research shows: Cagrilintide: what the research shows.
Where the accounts come from and how we read them
Sources: the Reddit forums r/cagrilintide (110 accounts), r/Peptides (13), r/CagriSema (9), r/Retatrutide (8) and r/Biohackers (2), 13 Oct 2024 to 6 Oct 2026. The posts were retrieved from a public Reddit archive. From first-person posts about cagrilintide, 300 were picked at random, and every one was read.
Coding: for each account we recorded the route, reported benefits and harms, how strong a harm was, whether and why the person stopped, length of use and other substances used at the same time. We kept accounts that reported some effect, some harm, or no effect. Questions and plans were left out. A harm was recorded when the person reported it during use, even if the cause was uncertain. Several posts by one person count as one person. One person can mention several things, so the shares in the tables do not add up to 100.
Check: an AI model read and classified the posts following written instructions. A second, separate AI run classified a random tenth (30 posts) again without seeing the first classification. The main fields matched: 27/30 (90%). One post looked like marketing and is not in the figures.
Whose accounts these are: routes mentioned: injection 126; the others did not say. The figures describe the writers and are not a recommendation. The products were not verified, so we do not know what people actually took.
Did cagrilintide help? The overall picture
Of 126 people, 36 (29%) reported benefit only, 38 (30%) both benefit and harm, 40 (32%) harm only and 12 (10%) neither.
Stopping. 18 people (14%) said they stopped or paused: 14 because of harms and 4 because they noticed no effect or for another reason.
| Overall picture: benefit, harm or neither | People | Share |
|---|---|---|
| Benefit only | 36 | 29% |
| Both benefit and harm | 38 | 30% |
| Harm only | 40 | 32% |
| Neither benefit nor harm | 12 | 10% |
Most common reported benefits
Of 126 people. 74 (59%) mentioned some benefit; the table lists every benefit reported.
| Reported | People | Share |
|---|---|---|
| Less appetite and food noise | 51 | 40% |
| Weight loss | 30 | 24% |
| More energy or alertness | 1 | 1% |
| Other benefit | 5 | 4% |
Share = people / 126.
Most common reported harms
Of 126 people. 78 (62%) mentioned some harm; 7 said explicitly they had none.
| Reported | People | Share |
|---|---|---|
| Fatigue | 35 | 28% |
| Nausea | 22 | 17% |
| Food aversion or eating too little | 15 | 12% |
| Mood or anxiety | 10 | 8% |
| Injection site pain or reaction | 6 | 5% |
| Vomiting | 6 | 5% |
| Heartburn, reflux or burping | 5 | 4% |
| Allergic reaction, hives or rash | 4 | 3% |
| Constipation | 3 | 2% |
| Diarrhoea | 2 | 2% |
| Headache | 2 | 2% |
| Insomnia | 2 | 2% |
| Other, rarer harm | 24 | 19% |
| Harms mentioned but not named | 1 | 1% |
Share = people / 126.
How severe were the harms?
Of the 78 people who described how strong a harm was, 29 (37%) described it as mild, 42 (54%) as clearly bothersome and 7 (9%) as severe. The strength is the writer's own description, not a doctor's assessment.
| Strength of the harm as the writer described it | People | Share |
|---|---|---|
| Mild: minor and manageable | 29 | 37% |
| Clearly bothersome: several days, sleep or work affected | 42 | 54% |
| Severe: emergency visit, hospital or unable to function | 7 | 9% |
Harms known from research and regulators: What are the side effects of cagrilintide?
How long did people use cagrilintide?
110 of 126 people (87%) said how long they had been using it at the time of writing. Where one person wrote several posts, the longest stated time counts.
| Stated length of use | People | Share |
|---|---|---|
| Under a week | 47 | 43% |
| 1-4 weeks | 39 | 35% |
| 1-3 months | 18 | 16% |
| Over 3 months | 6 | 5% |
Many people post partway through, often in the first days or as soon as harms start, so short times are over-represented. The numbers describe the writers; they do not say how long it should be used.
Other substances at the same time
87 of 126 people (69%) used other substances at the same time. The most common: retatrutide (37), tirzepatide (36) and semaglutide (18). Then the account cannot tell which substance had the effect.
About dosing
We do not repeat the amounts or ways of use people mention, and we give no dosing or how-to instructions. A safe dose is not known. Doses used in studies, with sources: Cagrilintide dosage in studies. Legal status: Is cagrilintide legal in Finland?
What can be concluded?
Less appetite and weight loss were the most common reported benefits, and tiredness was a more common harm than nausea. Because most used cagrilintide with a GLP-1 drug, the figures describe combined use.
The accounts prove neither that it works nor that it is safe. The writers are self-selected, the product contents are unknown, many used several substances at once, and placebo effects can be large. The research and its evidence levels: Cagrilintide: what the research shows.
Quotes
Short excerpts in the writers’ own words. Writers’ names and links are not shown. We picked quotes from every group: benefit, both benefit and harm, no effect, harms and people who stopped.
-
"What I am experiencing is that food noise has gone down a lot."
r/cagrilintide, 2024-12, Injected on its own after two GLP-1 drugs had not helped. Appetite control was by far the most common benefit reported in the sample.
-
"The stall seems over. I’ve definitely got my appetite suppression back"
r/Retatrutide, 2024-11, Added alongside retatrutide after weight loss had stalled. Almost everyone used it together with another weight loss drug.
-
"The fatigue from the Cagri and Tirz is rough"
r/cagrilintide, 2025-04, Four months alongside tirzepatide. The writer beat their weight goal and praises it, but the fatigue was hard. Fatigue was the most common harm reported in the sample.
-
"I've literally felt nothing. No side effects, no weight loss, I'm hungrier than ever."
r/cagrilintide, 2025-02, Four weeks alongside retatrutide.
-
"It's not doing much for me yet in terms of appetite supression and I am SO damn tired. Struggling to keep my eyes open at work."
r/cagrilintide, 2025-06, Injected. Nausea and aversion to food were the most common harms after fatigue.
-
"Just nothing feels worth doing, and nothing really brings any pleasure."
r/Retatrutide, 2026-02, Added alongside retatrutide a month earlier. The writer judged that cagrilintide worsened the loss of pleasure and stopped it.
Other summaries made with the same method: BPC-157 user experiences, Retatrutide user experiences, Semaglutide user experiences, Tirzepatide user experiences, Liraglutide user experiences, NAD+ user experiences, MOTS-c user experiences and user experiences with collagen and skin peptides.
Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.